Vor Biopharma

VOR

Market cap $195M

Overview Fund Activity

1.54 USD

+0.02

1.32%

At close Updated Sep 18, 2:44 PM EDT

1 day

1.32%

5 days

-14.44%

1 month

-24.51%

3 months

619.63%

6 months

86.33%

Year to date

37.5%

1 year

64.85%

5 years

-95.89%

10 years

-95.89%

About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Employees: 168

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,506% more call options, than puts

Call options by funds: $9.81M | Put options by funds: $611K

113% more capital invested

Capital invested by funds: $43.1M [Q1] → $91.8M (+$48.7M) [Q2]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

2.49% less ownership

Funds ownership: 48.13% [Q1] → 45.64% (-2.49%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

24% less funds holding

Funds holding: 45 [Q1] → 34 (-11) [Q2]

58% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 19

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$0.4

74% downside

Avg. target

$1.47

5% downside

High target

$3

95% upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth	$3	Buy Reiterated	14 Aug 2025
Baird Jack Allen	$1	Neutral Maintained	27 Jun 2025
Wedbush David Nierengarten	$0.4	Neutral Reiterated	26 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about VOR published over the past 30 days

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

YANTAI, China , Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an oral presentation at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting.

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California.

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D.

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Results reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN).

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference Fireside Chat: Tuesday, September 2nd, 2025, at 11:15am ETLocation: Boston, MA A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 6,959,013 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,491,217 shares of Vor Bio's common stock to seven newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren's disease.

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

See News Rankings

Charts implemented using Lightweight Charts™